{"name":"Fuji Yakuhin Co., Ltd.","slug":"fuji-yakuhin-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"FFI-1010","genericName":"FFI-1010","slug":"ffi-1010","indication":"Relapsed or refractory mantle cell lymphoma","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"14C-FYU-981","genericName":"14C-FYU-981","slug":"14c-fyu-981","indication":"Type 2 diabetes","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"FYU-981","genericName":"FYU-981","slug":"fyu-981","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"FFI-1010","genericName":"FFI-1010","slug":"ffi-1010","phase":"phase_3","mechanism":"FFI-1010 is a small molecule inhibitor of the Bruton's tyrosine kinase (BTK) enzyme.","indications":["Relapsed or refractory mantle cell lymphoma","Relapsed or refractory marginal zone lymphoma"],"catalyst":""},{"name":"14C-FYU-981","genericName":"14C-FYU-981","slug":"14c-fyu-981","phase":"phase_2","mechanism":"14C-FYU-981 is a selective and potent inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2).","indications":["Type 2 diabetes"],"catalyst":""},{"name":"FYU-981","genericName":"FYU-981","slug":"fyu-981","phase":"phase_3","mechanism":"FYU-981 is an investigational therapeutic agent in phase 3 development by Fuji Yakuhin Co., Ltd.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOY2xBdjBXZkJBX2FwaFk0NFktRlFndktXdkQxUDc4SHBqRTZ1MnZVejdSZFpRLU5oc0ZUWDNoMG5WTVplM0NKR2FucGVzeUpfMnpvUUVnMHRRSGpjbTNmY19zTEZncl9TYkpyTndqNjBCajBhTW5rOFNpakdGODlHQ05n?oc=5","date":"2025-10-01","type":"pipeline","source":"pharmaphorum","summary":"Crystalys emerges with $205m, and other biofinancings - pharmaphorum","headline":"Crystalys emerges with $205m, and other biofinancings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxNalMwQkNibUNDcVZFZGNqYm5oWUhjWHc1UnNaTTlJY1ludnJueVVCdl9VVlhIZTZLcER0bDI3RmVLbWl6TEFwUnZrbm96MWVSajhnX0t4VTVIRjliblQ2U1VYODB6UEZybUo2T2ttYnNrVXcwLTAzYTY0OFVBN1p4ZHFOdDgzS1d0b1YteGxpSUZURDVsM3RYN1BHV0pZcnlvN0s4THZxZmx6aE1yVzNDMVd6Q0NnVDRGcGxUR0MwMzg0OW13Nm5BVW5WWkJaTjhveExHTFQxQmVUNDZnRl9WcXoxa0Y3UQ?oc=5","date":"2025-09-30","type":"trial","source":"Reuters","summary":"Crystalys Therapeutics launches with $205 million funding round for trials of gout drug - Reuters","headline":"Crystalys Therapeutics launches with $205 million funding round for trials of gout drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOVDl5b0ZpOG91ZXMxeG5fREZOd1MwRkM3bTRsSVUyWnhtcFJ1MTdxNmpuZFZWYVlQWDljdE4yQ2JJaWxrQW9hOERXazJtVWJjOWZXTHB2S3BKSzRiX3VxbkVCUWdrdm96aVByZjUzcnZqRGVrMU5zODk5a25MLVF4SlZ2XzRKZGxOODdQZUZsWlc?oc=5","date":"2025-09-30","type":"pipeline","source":"BioPharma Dive","summary":"Crystalys debuts with $205M and plans for a better gout drug - BioPharma Dive","headline":"Crystalys debuts with $205M and plans for a better gout drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE9mTUhPdzRSWUR6ZEVSVUltT2dDM2Y4QzJiOVNUbDgxb2VDZXoyTkM1NmViVnE4QmY2dTN5UWV3WFMzMzQ3cTZ1cGxhTjEtU2d3ekVPRUJJTmJxYUk?oc=5","date":"2025-07-14","type":"pipeline","source":"Eisai","summary":"“URECE®” (Dotinurad) Launched in China as a treatment for Gout - Eisai","headline":"“URECE®” (Dotinurad) Launched in China as a treatment for Gout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxQYjFXejVwdTAxbk9aYVQ2ci1ySm9aY2lsTV9naGdsMTVsOFlZdHdXRVVmeG56bUl5ZmNHUlI5cUl1Mi1yVEdDLXR4c0FCSndjUVlRWHBkVHNacmY0dGNxQVZyMFA5YjBuTzNNV2tDLWZ0X1c3X0g4U1hQOFJsTHQ1UEtIMktpY3hJWGRJSDV3U1lxVHJhWjQ4SWFiZ25oSjBqRDNyUHF4RTAxOG9FblRlZEJOVG5icU5OSzlBRGpWT2loSkVvUVdWTV9PcnM5T0JLd3h1M3ZSNEFaLUNUeGI3RVY5OHBIdw?oc=5","date":"2022-05-19","type":"pipeline","source":"BioPharma APAC","summary":"Eisai and FUJI YAKUHIN will provide new treatment options for hyperuricemia and gout in Five ASEAN Countries - BioPharma APAC","headline":"Eisai and FUJI YAKUHIN will provide new treatment options for hyperuricemia and gout in Five ASEAN Countries","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE9mdml1NHlRLWJKcGdIRXFFLVVReHNJNGRBYlllZ1FsRnloVG1sMlRMSXJ3b0p1c05hYU9WeV9pTXpNNk8wcGtiSXg2UjFWTTB4d2RfYl91anRTYkxIZzlGVEJRTXItdXYtYlRN?oc=5","date":"2022-02-04","type":"pipeline","source":"Wiley Online Library","summary":"Effect of carperitide on the 1 year prognosis of patients with acute decompensated heart failure - Wiley Online Library","headline":"Effect of carperitide on the 1 year prognosis of patients with acute decompensated heart failure","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":2,"phase_2":1},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}